Tóth, G., Szöőr, Á., Simon, L., Yarden, Y., Szöllősi, J., & Vereb, G. (2016). The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. MAbs.
Citação norma ChicagoTóth, Gábor, Árpád Szöőr, László Simon, Yosef Yarden, János Szöllősi, and György Vereb. "The Combination of Trastuzumab and Pertuzumab Administered At Approved Doses May Delay Development of Trastuzumab Resistance By Additively Enhancing Antibody-dependent Cell-mediated Cytotoxicity." MAbs 2016.
Citação norma MLATóth, Gábor, et al. "The Combination of Trastuzumab and Pertuzumab Administered At Approved Doses May Delay Development of Trastuzumab Resistance By Additively Enhancing Antibody-dependent Cell-mediated Cytotoxicity." MAbs 2016.